PRMT5 regulates breast cancer cell growth through epigenetic silencing of DKK1 and DKK3, which are WNT/β-CATENIN pathway antagonists, thus resulting in up-regulation of WNT/β-CATENIN proliferative signaling [50]. Here, DKK3 is linked to breast carcinoma.